Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Diagnostics Division regional sales Growth driven by Asia Pacific and North America Sales YTD CHFm & % of total sales Total YTD Sales = 9,948 Sales growth at CER Diagnostics Division GLOBAL 559 6% 3,350 / 33% 3,171/ 32% 2,868 / 29% EMEA* ■NAM APAC ■ LATAM CER-Constant Exchange Rates (avg. full year 2021); * Europe, Middle East and Africa 11% -14% EMEA* 34% NAM 39% APAC | 2% LATAM Roche 189

View entire presentation